Kintor Pharmaceutical Limited

Kintor Pharma's KX-826 Shows Statistically Significant Hair Growth in US Phase II Trial for Male Pattern Baldness

- Kintor Pharma's KX-826 demonstrated statistically significant hair growth improvement in a US Phase II trial for male androgenetic alopecia, with the 0.5% twice-daily dose increasing hair count by approximately 10 hairs per cm² after 24 weeks (P=0.0088). - The randomized, double-blind, placebo-controlled study enrolled 123 male patients with moderate to severe hair loss, showing a clear dose-response relationship and favorable safety profile with only mild local scalp sensitivity reported. - The company plans to initiate Phase III trials globally following FDA meetings, with 0.5% twice-daily identified as the optimal dosing regimen for advanced development. - Multiple ongoing trials in China and the US are evaluating KX-826 for both male and female pattern hair loss, with Phase III enrollment for male AGA in China already completed.